In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 2 days of free consultation

 

Comparison of serum selenium and thyroid hormones in patients with acute myocardial infarction, chronic heart failure and healthy volunteers.

Session Poster Session 2

Speaker Magdalena Maria Fraczek-Jucha

Congress : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Comorbidities
  • Session type : Poster Session
  • FP Number : P1064

Authors : MM Fraczek-Jucha (Krakow,PL), M Kabat (Krakow,PL), B Szlosarczyk (Krakow,PL), J Nessler (Krakow,PL), A Gackowski (Krakow,PL)

Authors:
MM Fraczek-Jucha1 , M Kabat2 , B Szlosarczyk2 , J Nessler2 , A Gackowski2 , 1Jagiellonian University Medical College, Dep. of Emergency Medical Care, Dep. of Coronary Disease and Heart Failure, John Paul II Hospital - Krakow - Poland , 2Jagiellonian University Medical College, Department of Coronary Disease and Heart Failure, John Paul II Hospital - Krakow - Poland ,

Citation:

Background/Introduction: Selenium (Se) is incorporated in many selenoproteins i.e.: glutathione peroxidase (GPX) and iodothyronine deiodinases. Oxidative stress is increased in acute coronary syndromes (ACS) and heart failure (HF). In case of Se deficiency both GPX activity and thyroid hormones conversion may be decreased and have negative influence on cardiovascular system.

Purpose: We sought to evaluate Se levels in Polish patients with myocardial infarction (MI), heart failure (HF) and healthy volunteers in relation to thyroid hormones levels.

Methods:
The study group: We studied 143 persons: 54 consecutive patients with acute MI (group MI), 59 consecutive patients with decompensated HFrEF, (group HF) and 30 healthy volunteers (group C).
Exclusion criteria: thyroid dysfunction, severe systemic disease, treatment with amiodarone, steroids or propranolol.
Laboratory tests: TSH, fT3, fT4, Se levels were analysed.

Results: Se levels were lowered in both MI and HF patients in comparison to healthy controls (Table 1, Figure 1). Patients with MI and HF presented higher levels of TSH and lower levels of fT3 and fT3/fT4 ratio in comparison to controls (Table 1).
There was a moderate correlation between Se and: fT3 (r=0.390, p<0.0001) and fT3/fT4 ratio (r=0.4294, p<0.0001).

Conclusions: Se deficiency is frequent, unrecognized finding in both patients with acute MI and chronic HF in comparison to healthy volunteers. Further studies are needed to investigate if Se deficiency may play a negative role in patients with MI, and HF.

Characteristics

Group MI

n= 54

Group HF

n= 59

Group C

n= 30

p-value

Age, years

61.00

(53.75; 67.25)

65.00

(59.00; 74.00)

61.50

(57.50; 68.75)

0.0837

Male sex, n (%)

47 (87.04%)

48 (81.36%)

25 (83.33%)

0.7104

Smoking, n (%)

33 (61.11%)

21 (35.59%)

8 (27.59%)

0.0035 a,b

BMI, kg/m2

26.18

(24.76; 30.79)

28.41

(25.50; 32.28)

30.11

(27.36; 34.76)

0.0127 b

Selenium, µg/l

65.91

(55.15; 76.10)

59.74

(47.73; 70.66)

93.18

(84.20; 99.10)

<0.0001 b,c

Selenium deficiency,

n (%)

38 (70.37%)

44 (74.58%)

3 (10.00%)

<0.0001 b,c

TSH, µIU/ml

2.23 (1.20; 3.11)

1.60 (1.16; 2.03)

1.08 (0.68; 1.80)

0.0002 b,c

fT3, pmol/l

4.21(±0.69)

4.16(±0.94)

4.99(±0.66)

<0.0001 b,c

fT4, pmol/l

15.96(±2.27)

17.95(±2.98)

15.31(±1.91)

<0.0001 a,c

fT3/fT4 ratio

0.27(±0.04)

0.24(±0.06)

0.33(±0.05)

<0.0001a,b,c

Table legend: a - p<0.05 between group MI and HF, b - p<0.05 between group MI and C, c- p<0.05 between group HF and C.

This content is currently on FREE ACCESS, enjoy another 2 days of free consultation

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are